<b>Gapping up <br/>In reaction to strong earnings/guidance:</b><br/>CLNE +19.2%, OPGN +15.4%, ADVM +12.7%, YELP +12.6%, SUNW +10.7%, VRNS +9.6%, DXPE +8.9%, BBSI +8.6%, COTV +7.7%, DHT +7.7%, NH +7.3%, YRD +7.3%, HCHC +7%, WATT +6.7%, (also announces $20 mln private placement), RL +6.6%, INFI +5.6%, CDXS +5.3%<br/>LITE +4.9%, HALO +4.8%, RYI +4.4%, JD +4.1%, XONE +3.7%, CEL +3.7%, OXLC +3.4%, HLIT +3.3%, CRME +3.2%, (also XYDALBA has been approved by the EMA for administration as a single, 30 minute, 1500mg infusion), AG +3.1%, ICLD +2.9%, CPRX +2.8%, ARMK +2.7%, PUK +2.5%, EDIT +2.4%, TCS +2.4%<br/>TAHO +1.9%, OTIV +1.8%, WAGE +1.7%, RBCN +1.7%, ICL +1.5%, PTLA +1.1%, AEZS +1.1%, IEC +1%<br/>Select metals/mining stocks trading higher: EGO +4.9%, MUX +4.4%, BTG +4%, GFI +3.9%, KGC +3.9%, SWC +3.3%, CDE +3.2%, HL +3.1%, FCX +3%, SLV +2.9%, ABX +2.8%, GDX +2.7%, GOLD +2.6%, AU +2.6%, GG +2.5%, AUY +2.3%, NEM +2.2%, MT +1.6%, BHP +1.5%, IAG +1.2%, GLD +1.1%<br/><br/><b>Other news:</b><br/>APRI +27.9% (announces that Ferring Pharmaceuticals, the Company's new partner in Germany, has received the German marketing authorization for Vitaros)<br/>VTVT +15.5% (announces 'positive' topline results from a Phase 2b study of TTP399; achieves primary endpoint)<br/>CBMX +12.3% (announces that Universal Diagnostic Labs will market and distribute its chromosomal microarray miscarriage analysis test in both Northern and Southern California)<br/>VSAR +11.5% (Versartis and Teijin LImited enter into an exclusive license and supply agreement for the development and commercialization of somavaratan in Japan; will receive an upfront payment of $40 million )<br/>PLX +11.1% (announces additional 'positive' data from its phase I/II clinical trial of PRX-102 for the treatment of Fabry disease)<br/>OCN +7.9% (S&P raised its ranking on Ocwen Loan Servicing LLC Commercial Servicer, Ocwen Loan Servicing LLC Residential Master Servicer to Average)<br/>KTOV +6.8% (receives US patent for its lead drug candidate KIT-302)<br/>TOPS +5.9% (announces delivery of sixth newbuilding vessel & completion of six-vessel newbuilding program)<br/>JBLU +1.6% (reports July 2016 prelim traffic)<br/>Analyst comments:<br/>ZIOP +6.4% (upgraded to Market Perform from Underperform at Wells Fargo<br/>SSL +3.1% (upgraded to Overweight from Equal Weight at Morgan Stanley)<br/>ASPS +2.7% (upgraded to Buy at Compass Point)<br/>PHG +2.2% (upgraded to Buy from Neutral at UBS)<br/><b>Gapping down<br/>In reaction to disappointing earnings/guidance:</b><br/>GEVO -32.6%, MYGN -30%, SPWR -29%, (also announces restructuring due to industry conditions), WGBS -24.8%, TDW -17%, (updates status of discussions with lenders / noteholders ), PRGO -12.7%, YUME -10.2%<br/>SIF -9.4%, GALE -7%, CYBR -5.5%, DPLO -5.1%, LSCC -4.8%, ARWR -4.5%, OHRP -4.4%, CALL -4.3%, ALDX -4.2%, KORS -4.2%, SEDG -3.8%, OA -3.8%, WEN -3.8%, CALA -3.4%, VSAT -3.3%<br/>OMER -2.8%, SPPI -2.1%, NVAX -2%, HTM -1.8%, CTSO -1.8%, (thinly traded), DIS -1.4%, (also Acquires Minority Stake in BAMTech; Disney Investment will Accelerate Growth of Leading Technology and Direct-To-Consumer Video Streaming Company), MATR -1.4%, SPHS -1.4%, JAZZ -1%<br/><b>Other news:</b><br/>GBSN -9.1% (discloses further issuance of shares to certain holders of its 2015 Notes)<br/>RPRX -8.6% (light volume; enters into equity distribution agreement to offer and sell up to $10 mln in shares of common stock)<br/>CSIQ -5.5% (following SPWR earnings/guidance/restructuring news)<br/>X -4.2% (priced 18.9 mln shares common stock offering (upsized from 17 mln) at a public offering price of $23/share)<br/>FSLR -3.6% (following SPWR earnings/guidance/restructuring news)<br/>CLF -3.4% (announces underwritten public offering of $300 mln of its common shares)<br/>JKS -3.2% (in sympathy with SPWR earnings)<br/>ZBH -3.1% (pricing of a ~7.44 mln share secondary common stock offering at $129.75/share by selling shareholders)<br/>LY -2.9% (updates on Monarch 2 phase 3 trial of Abemaciclib; an independent Data Monitoring Committee recommended to continue the study without modification as the interim efficacy criteria were not me)<br/>VWR -2.8% ( commences 8 mln common stock offering by selling stockholder Varietal Distribution Holdings )<br/>LOAN -1.8% (prices underwritten public offering of 672,269 common shares at a price to the public of $5.95 per share)<br/>CONE -1.7% (CyrusOne commenced the public offering of 6.8 mln shares of common stock-including 3.4 mln by the Forward Purchaser or its affiliate in connection with the forward sale agreement )<br/>PANW -1.2% (following CYBR earnings)<br/>TSL -1.1% (following SPWR earnings/guidance/restructuring news)<br/><b>Analyst comments:</b><br/>NE -2.4% (downgraded to Sell from Hold at Argus)<br/>RBS -0.8% (downgraded to Hold from Buy at Investec)<br/><br/>Briefing.com